Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying ...

The FDA has approved Steqeyma® (ustekinumab-stba), a biosimilar to Stelara®, for the treatment of various chronic ...

Topline data were announced from two phase 3 trials evaluating deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor, in adults with active psoriatic arthritis (PsA). POETYK PsA-1 (ClinicalTrials.gov ...

Shares of Bristol Myers Squibb ($BMY) were in the spotlight on Friday after the U.S. Food and Drug Administration approved an ...

Bristol Myers on Monday said the two Phase 3 studies met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving at least a 20% improvement in signs and ...

(RTTNews) - Drug maker Bristol-Myers Squibb Co. (BMY) Monday announced positive topline results from two pivotal Phase 3 trials evaluating Sotyktu (deucravacitinib) in adults with active psoriatic ...

Across 2024, top immunology news focused on ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis, ...

Long-term treatment with guselkumab is associated with sustained improvements in joint/skin symptoms and disease activity among patients with active PsA.

A Bristol Myers Squibb drug that was first in its class to hit a certain immunological target now has positive data from two pivotal tests in psoriatic arthritis that could support expanding use ...

Originally approved in 2009, Stelara patents began expiring in 2023, leading to an influx of recent biosimilars.

in adults with active psoriatic arthritis (PsA), with both trials hitting their endpoints. In both trials, patients treated with Sotyktu, saw a greater treatment response, as measured by the ...